Your browser doesn't support javascript.
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.
Muruato, Antonio E; Fontes-Garfias, Camila R; Ren, Ping; Garcia-Blanco, Mariano A; Menachery, Vineet D; Xie, Xuping; Shi, Pei-Yong.
  • Muruato AE; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Fontes-Garfias CR; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
  • Ren P; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Garcia-Blanco MA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
  • Menachery VD; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Xie X; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • Shi PY; Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Nat Commun ; 11(1): 4059, 2020 08 13.
Article in English | MEDLINE | ID: covidwho-720832
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Clinical Laboratory Techniques / Antibodies, Neutralizing / Betacoronavirus Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-17892-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Clinical Laboratory Techniques / Antibodies, Neutralizing / Betacoronavirus Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-17892-0